ClinicalTrials.Veeva

Menu

Molecular Analysis of Patients With Neuromuscular Disease

Boston Children's Hospital logo

Boston Children's Hospital

Status

Enrolling

Conditions

Neuromuscular; Disorder, Hereditary
Duchenne/Becker Muscular Dystrophy
Limb-girdle Muscular Dystrophy

Study type

Observational

Funder types

Other
NIH

Identifiers

NCT00390104
5R01NS080929 (U.S. NIH Grant/Contract)
03-12-205

Details and patient eligibility

About

The purpose of this study is to identify new genes responsible for neuromuscular disorders and study muscle tissue of patient with known neuromuscular disease, as well as their family members. We are interested in recruiting many types of neuromuscular disease including; Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and limb-girdle muscle dystrophy (LGMD). There are still many patients diagnosed with muscular dystrophy with no causative gene implicated in their disease. Using molecular genetics to unravel basis of these neuromuscular disorders will lead to more accurate diagnosis/prognosis of these disorders which will lead to potential therapies.

Full description

We are looking to discover new disease genes responsible for the neuromuscular diseases found in our participants and their families. Our research lab has a long history of identifying novel genes responsible for various forms of neuromuscular disease including; DMD gene, the sarcoglycans, obscurin, and filamin. Each discovery has resulted in advances in our ability to develop diagnostic tests which benefit patients and their families by providing accurate diagnosis, presymptomatic and/or prenatal testing. Genotype-phenotype correlation studies have increased our understanding of the natural history of these rare disorders benefiting patients through better prognostic determinations by clinicians. Biochemical and pathological analysis of muscle biopsy samples in patients with known and unknown types of neuromuscular disease has led to new insights into disease pathophysiology, which we hope will aid in finding new treatments.

Enrollment

1,000 estimated patients

Sex

All

Ages

1 week to 100 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

The samples used in this study will be derived from individuals at risk for, or suffering from, neuromuscular disease, generally resulting in clinical weakness of one or more muscle groups and their family members.

Inclusion criteria:

  1. having a clinical and/or pathological diagnosis of a muscular dystrophy
  2. being the first degree relative of someone with such a diagnosis
  3. having had a muscle biopsy if diagnosed with a neuromuscular disease
  4. willingness to provide a skin biopsy for research only

Exclusion Criteria:

  1. not having a neuromuscular diagnosis in you or a family member
  2. not wishing to participate
  3. being incapable of giving consent and not having a legal guardian willing or able to do so

Trial contacts and locations

1

Loading...

Central trial contact

Elicia A Estrella, MS, LCGC; Casie Genetti, MS,LCGC

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems